Tadalafil Lilly ICOS

Research output: Contribution to journalReview articleResearchpeer-review

9 Citations (Scopus)
Original languageEnglish
Pages (from-to)60-65
Number of pages6
JournalCurrent Opinion in Investigational Drugs
Volume4
Issue number1
StatePublished - 1 Jan 2003

Fingerprint

3',5'-Cyclic-GMP Phosphodiesterases
Carbolines
Phase III Clinical Trials
Phase II Clinical Trials
Clinical Trials, Phase I
Phosphodiesterase Inhibitors
Phosphoric Diester Hydrolases
Erectile Dysfunction
Tadalafil

Cite this

@article{2b4928e5e98f45e1b93890ebbd1caa35,
title = "Tadalafil Lilly ICOS",
author = "David Rotella",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "4",
pages = "60--65",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Current Drugs Ltd.",
number = "1",

}

Tadalafil Lilly ICOS. / Rotella, David.

In: Current Opinion in Investigational Drugs, Vol. 4, No. 1, 01.01.2003, p. 60-65.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Tadalafil Lilly ICOS

AU - Rotella, David

PY - 2003/1/1

Y1 - 2003/1/1

UR - http://www.scopus.com/inward/record.url?scp=0037286720&partnerID=8YFLogxK

M3 - Review article

VL - 4

SP - 60

EP - 65

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 1

ER -